Data will soon show whether Avadel’s FT218 is more convenient than Jazz’s Xyrem, while Axovant will be looking for a dose response with its Parkinson’s gene therapy.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Last week's pivotal trial success could give Celgene a second AML drug, setting up a battle against Roche's Venclexta and idasanutlin.
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.